Merck: endometrial cancer treatment approved in Japan
(CercleFinance.com) - Merck and Eisai today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of Merck's Keytruda and Eisai's Lenvima for the treatment of unresectable, advanced or recurrent endometrial carcinoma that has progressed after cancer chemotherapy.
This is the first time that the combination of these two products has been approved in Japan, the companies said.
Patients will now be able to benefit from the first combination of immunotherapy and tyrosine kinase inhibitor that has significantly improved overall survival and progression-free survival compared to chemotherapy, Merck commented.
In addition to advanced endometrial carcinoma, Merck and Eisai add that they are also evaluating the combination of Keytruda and Lanvima in several cancer types with over 20 clinical trials.
Copyright (c) 2021 CercleFinance.com. All rights reserved.